Patentability of Bio-Printed Organs and Tissues: Ethical Boundaries and IP Rights

Abstract

Emerging three-dimensional (3D) bioprinting technologies, which enable layer-by-layer deposition of living cells and biomaterials to mimic complex tissue architectures as well as organ constructs, have emerged as powerful tools for regenerative medicine. However, they bring up difficult questions about intellectual property (IP) and ethics. The Patents Act, 1970 (as amended) is the law governing patentability, which requires novelty, non-obviousness and industrial applicability and including no inventions against morality (Section 3(b)), and medical/surgical treatment methods (Section 3(i)). This paper considers how bioprinted organs and tissues would be treated under India’s patent law. In this context, we address the relevant patent considerations – novelty and inventive step (for biomimetic products), and statutory exclusions in sections 3(b), 3(c), 3(i) and 3(j) – in India. Comparative reference is made to the US (USPTO) and European (EPO) systems and WIPO practices. Here in US, SCOTUS and post-AIA (§101, §33) control eligibility and recommend only patent bioprinting methods, not organs. The EU/EPO bases the Biotech Directive, accepts (but technically produced) isolated human material but makes exceptions to inventions contrary to “public order or morality” (hence no human cloning). The core ethical issues—respect for human dignity, the commodification of the body, patient autonomy—are present across the board. For instance, the application of embryonic stem cells in designs evokes respect for unborn life. While we highlight global trends (such as Organovo securing a U.S patent for tissue printing), we also want to emphasize that India’s domestic IP jurisprudence is still in its nascent stage. Therefore, India should define the middle path between innovation and bioethics of not allowing patents on technical methods and not allowing it on non-embryonic composition of matter while still upholding human dignity and ensuring equitable access. This might include the steps such as: ethical sourcing of cells; patient consent/ rights in bioprinting innovations and, perhaps even making patent grants contingent upon benefit sharing.